matter news
MATTER announces programs focused on innovation in the life sciences
Chicago’s life sciences ecosystem is taking off: In the first half of this year, AveXis sold for $8.7 billion, the largest acquisition of a Chicago-area biotechnology company to date. Iterum Therapeutics, Xeris Pharmaceuticals and Aptinyx all went public, as did Exicure (whose CEO, David Giljohann, will be at MATTER in October for Tales from the Trenches). Between 2013 and 2017, 44% of funding …
Read more